This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Valerian Root

Valeriana officinalis is the most heavily marketed botanical sedative in the West, but the cleaner you look at the data, the smaller the signal gets.

Aliases (6)
VALERIAN ROOT · Valeriana officinalis · valerian · garden valerian · all-heal · vandal root
TYPICAL DOSE
300–600 mg standardized extract
ROUTE
CYCLE
STORAGE

Overview

What is Valerian Root?

Valeriana officinalis is the most heavily marketed botanical sedative in the West, but the cleaner you look at the data, the smaller the signal gets. Bent's 2006 meta-analysis found a modest dichotomous "improved sleep" effect (RR ~1.8) on subjective questionnaires; the same review flagged heavy publication bias. Taibi 2009 — the cleanest PSG trial — was outright null on objective sleep latency, total sleep time, and actigraphy. Smell is universally bad (isovaleric acid plus valerenic acid), the morning hangover is real in a meaningful subset of users, and the bioactive complex is so unstable that two bottles of "300mg standardized extract" can differ 5-fold in valepotriate content. For a 20yo MMA athlete with V4 already covering magnesium glycinate + apigenin + L-theanine + sleep hygiene + glycine, valerian is strictly inferior. SKIP for Dylan. Possible-use for sleep-onset insomnia where modern tools have failed, never as a first move.

Pharmacokinetics

·
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK

Peptide Interactions

Hops (Humulus lupulus, 60-120 mg)
Synergistic

better RCT support as combo than monotherapy. Ze 91019 product is the canonical formulation; works on similar GABA-A pathway.

Lemon balm (Melissa officinalis, 240 mg)
Synergistic

anxiety + sleep combo. Adds mild serotonergic + acetylcholine modulation.

Magnesium glycinate (200-400 mg)
Synergistic

additive GABAergic + NMDA antagonist relaxation. The single best mineral co-stack for sleep.

L-theanine (200 mg)
Synergistic

alpha-wave promotion + glutamate modulation. Smooths anxiety dimension.

Apigenin (50 mg)
Synergistic

another GABA-A PAM. Similar mechanism, modest dose-additive sedation.

Glycine (3 g)
Synergistic

separate mechanism (NMDA glycine site, body-temp drop). Stacks cleanly.

Benzodiazepines
Avoid

Additive GABAergic depression; theoretical respiratory risk at high combined doses. Clinical interaction reports exist.

Z-drugs (zolpidem, eszopiclone, zaleplon)
Avoid

Same logic. Skip.

Phenibut
Avoid

Same logic plus much stronger CNS depression; combined effect = oversedation, motor impairment.

Alcohol
Avoid

Additive sedation; multiple case reports of profound somnolence.

Opioids
Avoid

Additive respiratory depression risk at high doses.

Sedating antihistamines (diphenhydramine, doxylamine)
Avoid

Additive sedation + anticholinergic load.

What to Expect

  • Week 1
    Tolerability and dose-response.
  • Week 2-4
    Early effect window.
  • Week 4-8
    Peak benefit assessment.
  • Week 8+
    Cycle decision point.

Side Effects & Safety 6

Side Effects

  1. 1Smell/taste/burp — Universal. Isovaleric acid + valerenic acid metabolites smell like sweaty gym socks. Capsules contain it; tinctures and teas don't.
  2. 2Mild morning grogginess — 10–20% of users; worse at >600mg or with concentrated extracts. The "valerian hangover."
  3. 3GI upset — nausea, abdominal cramps, loose stools. ~5-10% of users at standard doses.
  4. 4Headache — uncommon, usually mild.
  5. 5Paradoxical agitation/insomnia/anxiety — small fraction; sometimes resolves with dose reduction, sometimes a permanent non-response.
  6. 6Vivid dreams or unusual dreaming — reported in community surveys; mechanism unclear (possibly REM rebound or 5-HT contribution).

When to Stop

  • Hepatotoxicity — Sporadic case reports of valerian-associated liver injury (elevated ALT/AST, occasionally cholestasis). Most reports are with multi-herb products (e.g., "Sleepytime + Valerian" combos, kava-valerian stacks) — usually multi-herb confounded. Direct causation in monotherapy is uncommon. Recommendation: avoid in known liver disease; monitor LFTs if using chronically with other hepatically-cleared compounds.
  • Withdrawal-like syndrome on abrupt discontinuation — At least one case report (Garges 1998) described autonomic withdrawal symptoms after stopping high-dose chronic valerian. Genuine GABAergic withdrawal is theoretically plausible but extremely rare at OTC doses.
  • Cardiovascular interactions — Occasional bradycardia/hypotension cases, usually with multi-CNS-depressant context.
  • Allergic reactions — Rare; dermatitis from topical contact more common than systemic.
  • Pregnancy / breastfeeding: Considered safe within typical OTC limits — no teratogenicity signals in animal or human data. Defer to OB if a Dylan-archetype partner is pregnant; pregnant individuals can use 400-600mg short-term for sleep with conservative caution.
  • Children: Not recommended <12; some pediatric trials in 4-12yo use 320mg/day with reported safety, but data thin. Default no.
  • Elderly: Use with care — falls risk from mild sedation; LFT monitoring if chronic.
  • Liver disease: Avoid — hepatotoxicity case reports plus complex hepatic metabolism makes it the wrong herb for compromised liver.
  • Pre-surgical: Hold ≥2 weeks before elective surgery — additive sedation with general anesthetics, possible GABA-A interaction with benzodiazepine premedication, theoretical bleeding risk via valepotriates.

References

Bent S et al. 2006 — Valerian for sleep: systematic review and meta-analysis (Am J Med)

pubmed.ncbi.nlm.nih.gov · 2006

16-RCT meta; RR ~1.8 for subjective sleep improvement; flagged publication bias.

View Study

Taibi DM et al. 2009 — Randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep (Sleep Med)

pubmed.ncbi.nlm.nih.gov · 2009

Null PSG/actigraphy/subjective trial in older women with insomnia; the cleanest negative data in the literature.

View Study

Fernández-San-Martín MI et al. 2010 — Effectiveness of valerian on insomnia: meta-analysis of RCTs (Sleep Med)

pubmed.ncbi.nlm.nih.gov · 2010

18-RCT meta-analysis; dichotomous benefit RR ~1.4; quantitative latency reduction non-significant.

View Study

Shinjyo N et al. 2020 — Valerian root in treating sleep problems and associated disorders: systematic review and meta-analysis (J Evid Based Integr Med, PMID 33086877)

pubmed.ncbi.nlm.nih.gov · 2020

Modern meta; whole-root at 450-1410mg ≥4 weeks more consistent; anxiety subgroup benefits more.

View Study

Recent herbal-medicines synthesis for insomnia (2024, PMID 38359657)

pubmed.ncbi.nlm.nih.gov · 2024

Network meta-analysis context; ashwagandha and lavender outrank valerian.

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources